Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study-Reference-Cited by-同舟云学术

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study

Published:2018-03-14 Issue:5 Volume:25 Page:457-464
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Brown A.¹^ORCID,Hézode C.²,Zuckerman E.³,Foster G. R.⁴,Zekry A.⁵,Roberts S. K.⁶^ORCID,Lahser F.⁷,Durkan C.⁷,Badshah C.⁷,Zhang B.⁷,Robertson M.⁷,Wahl J.⁷,Barr E.⁷,Haber B.⁷,

Affiliation:

1. Imperial College Healthcare NHS Trust London UK

2. Henri Mondor HospitalUniversity of Paris‐Est Creteil France

3. Liver UnitCarmel Medical Center Technion Faculty of Medicine Haifa Israel

4. Liver UnitQueen Mary University of London London UK

5. St George Hospital Clinical SchoolInflammation and Infection Research CentreUniversity of New South Wales Sydney NSW Australia

6. The Alfred Hospital Melbourne VIC Australia

7. Merck & Co., Inc. Kenilworth NJ USA

Funder

Merck

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12801

Reference20 articles.

1. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

2. EASL Recommendations on Treatment of Hepatitis C 2015

3. GaneEJ HylandRH AnD et al.High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection: ELECTRON‐1. Presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7‐11 2014; Boston MA.

4. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial;Kapoor R;Hepatology,2014

5. O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: A systematic review and meta-analysis;2023-03-31

2. A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection;Frontiers in Pharmacology;2021-09-09

3. Elbasvir and grazoprevir for the treatment of hepatitis C;Expert Review of Anti-infective Therapy;2021-01-17

4. Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials;Journal of Viral Hepatitis;2020-08-10

5. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis;Current Medical Research and Opinion;2020-06-24